Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_assertion type Assertion NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_head.
- NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_assertion description "[E2A-PBX1+ adult ALL should be considered for intensified treatment strategies and monitoring of minimal residual disease.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_provenance.
- NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_assertion evidence source_evidence_literature NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_provenance.
- NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_assertion SIO_000772 12580965 NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_provenance.
- NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_assertion wasDerivedFrom befree-20150227 NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_provenance.
- NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_assertion wasGeneratedBy ECO_0000203 NP610880.RAkyJQW86xwJK23cABBe4p6fUUZxBrnUfad4cNJZfU0do130_provenance.